HIF1A and hepatocellular carcinoma: Taken together, CANA exhibits anti-HCC effects by activating AMP-activated protein kinase (AMPK) and suppressing the HIF-1α/YAP/TAZ pathway, making it a forthcoming therapeutic option for HCC.